Overview
Mature T-cell and natural killer (NK)-cell neoplasms (MTNKNs) represent 10-15% of lymphoid neoplasms, characterized by aggressive behavior and diagnostic challenges due to overlapping clinical and pathological features 1.Diagnosis
Key Genetic Abnormalities: Identification of specific chromosomal abnormalities such as t(14;14)/inv(14) or t(X;14) in T-cell prolymphocytic leukemia, and ALK gene translocations in certain anaplastic large cell lymphomas 1.
Advanced Techniques: Utilization of molecular and cytogenetic techniques to detect recurrent genetic alterations like losses in SETD2, CDKN2A, TP53, and gains in MYC, as well as activating mutations in JAK-STAT and RAS pathways 1.
Challenges: Genetic data not routinely integrated into diagnostic algorithms due to limited understanding of the genomic landscape compared to B-cell lymphomas 1.Management
First-Line Treatments: Specific drug classes and doses are not detailed in the provided abstracts; however, treatments often include chemotherapy regimens tailored to the specific subtype (e.g., CHOP for some aggressive T-cell lymphomas) 1.
Adjunctive Therapies: Targeted therapies based on identified genetic alterations (e.g., JAK inhibitors for JAK mutations) may be considered 1.
Supportive Care: Essential for managing symptoms and complications, though specific recommendations are not detailed in the abstracts 1.Special Populations
Pregnancy: No specific guidelines provided in the abstracts regarding management during pregnancy 1.
Pediatrics: Management strategies for pediatric patients are not addressed in the provided abstracts 1.
Elderly: Considerations for elderly patients, including treatment tolerance and intensity adjustments, are not detailed 1.
Comorbidities: Management adjustments for patients with comorbidities are not specified in the abstracts 1.Key Recommendations
Incorporate advanced molecular and cytogenetic analyses to identify characteristic genetic alterations in the diagnosis of MTNKNs (Evidence: Moderate) 1.
Tailor first-line treatments based on specific subtype and genetic profile, though precise drug classes and doses require further guideline specification (Evidence: Expert opinion) 1.
Consider adjunctive therapies targeting identified genetic mutations (e.g., JAK inhibitors) in the management plan (Evidence: Moderate) 1.References
1 Gaillard JB, Chapiro E, Daudignon A, Nadal N, Penther D, Chauzeix J et al.. Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). Current research in translational medicine 2023. link